This fact sheet summarizes a systematic review of published studies to analyze how the cost-sharing features of prescription drug benefits may affect access to prescription drugs and, consequently, health outcomes.
The RAND Corporation has presented the first Victor R. Fuchs Research Award to a team from Carnegie Mellon University in Pittsburgh for publishing the best research paper with the potential to spawn new research in an underdeveloped area of health economics or health policy.
Many seniors quit taking drugs for chronic illnesses such as diabetes and high blood pressure when they exceed their drug plan's yearly spending limits. Even when drug benefits resume at the start of a new health plan year, a significant number do not resume their prescription medications.
This Research Brief summarizes the relationship between (1) co-payments and compliance for patients whose doctors prescribed cholesterol-lowering drugs, and (2) compliance and subsequent use of expensive health care services.
Cutting drug copayments on cholesterol-lowering medication for the sickest patients would avert nearly 80,000 hospitalizations and more than 31,000 emergency room visits each year — accounting for the more than $1 billion in savings.
The U.S. military health care system has experienced rapid growth in expenditures over the past decade. To lower costs, it should discourage retirees' use of retail pharmacies and carefully implement a three-tier drug benefit.
Examines the effects of Medigap prescription drug benefits on elderly prescription drug spending and Medicare spending in order to estimate the potential offset savings that the Medicare prescription drug program may generate.
Implementing a modest catastrophic benefit with low-income subsidies would provide valuable insurance to the Medicare population. It also would provide a fiscally prudent alternative, allowing policymakers to better gauge future program costs and beneficiary behavior.